Calcium Absorption and Bone Loss in Ovariectomized Rats Fed Varying Levels of Dietary Calcium

1999 ◽  
Vol 65 (1) ◽  
pp. 73-77 ◽  
Author(s):  
D. N. Kalu ◽  
P. B. Orhii

BioFactors ◽  
2004 ◽  
Vol 22 (1-4) ◽  
pp. 39-42 ◽  
Author(s):  
Moyuru Koshihara ◽  
Ritsuko Masuyama ◽  
Mariko Uehara ◽  
Kazuharu Suzuki


1998 ◽  
Vol 4 (3) ◽  
pp. 209-212 ◽  
Author(s):  
Masayoshi YAMAGUCHI ◽  
Masanori TEZUKA ◽  
Shigefumi SHIMANUKI ◽  
Mitsuo KISHI ◽  
Yoshihiro TUKADA


1995 ◽  
Vol 59 (2) ◽  
pp. 236-239 ◽  
Author(s):  
Osamu Chonan ◽  
Keisuke Matsumoto ◽  
Masaaki Watanuki


2011 ◽  
Vol 212 (2) ◽  
pp. 179-186 ◽  
Author(s):  
Rana Samadfam ◽  
Malaika Awori ◽  
Agnes Bénardeau ◽  
Frieder Bauss ◽  
Elena Sebokova ◽  
...  

Peroxisome proliferator-activated receptor (PPAR) γ agonists, such as pioglitazone (Pio), improve glycemia and lipid profile but are associated with bone loss and fracture risk. Data regarding bone effects of PPARα agonists (including fenofibrate (Feno)) are limited, although animal studies suggest that Feno may increase bone mass. This study investigated the effects of a 13-week oral combination treatment with Pio (10 mg/kg per day)+Feno (25 mg/kg per day) on body composition and bone mass parameters compared with Pio or Feno alone in adult ovariectomized (OVX) rats, with a 4-week bone depletion period, followed by a 6-week treatment-free period. Treatment of OVX rats with Pio+Feno resulted in ∼50% lower fat mass gain compared with Pio treatment alone. Combination treatment with Pio+Feno partially prevented Pio-induced loss of bone mineral content (∼45%) and bone mineral density (BMD; ∼60%) at the lumbar spine. Similar effects of treatments were observed at the femur, most notably at sites rich in trabecular bone. At the proximal tibial metaphysis, concomitant treatment with Pio+Feno prevented Pio exacerbation of ovariectomy-induced loss of trabecular bone, resulting in BMD values in the Pio+Feno group comparable to OVX controls. Discontinuation of Pio or Feno treatment of OVX rats was associated with partial reversal of effects on bone loss or bone mass gain, respectively, while values in the Pio+Feno group remained comparable to OVX controls. These data suggest that concurrent/dual agonism of PPARγ and PPARα may reduce the negative effects of PPARγ agonism on bone mass.



Nutrients ◽  
2014 ◽  
Vol 6 (12) ◽  
pp. 5853-5870 ◽  
Author(s):  
Zhiguo Zhang ◽  
Lihua Xiang ◽  
Dong Bai ◽  
Wenlai Wang ◽  
Yan Li ◽  
...  


2015 ◽  
Vol 230 (9) ◽  
pp. 2184-2201 ◽  
Author(s):  
Chao Fu ◽  
Dong Xu ◽  
Chang-Yuan Wang ◽  
Yue Jin ◽  
Qi Liu ◽  
...  


2015 ◽  
Vol 18 (12) ◽  
pp. 1349-1356 ◽  
Author(s):  
Jonggun Kim ◽  
Hyung Kwan Kim ◽  
Saehun Kim ◽  
Ji-Young Imm ◽  
Kwang-Youn Whang


Sign in / Sign up

Export Citation Format

Share Document